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Abstract
Chagas’ disease is responsible for significant mortality and morbidity in Latin America. Cur-
rent treatments display variable efficacy and have adverse side effects, hence more effec-
tive, better tolerated drugs are needed. However, recent efforts have proved unsuccessful
with failure of the ergosterol biosynthesis inhibitor posaconazole in phase II clinical trials
despite promising in vitro and in vivo studies. The lack of translation between laboratory
experiments and clinical outcome is a major issue for further drug discovery efforts. Our
goal was to identify cell-based assays that could differentiate current nitro-aromatic drugs
nifurtimox and benznidazole from posaconazole. Using a panel of T. cruzi strains including
the six major lineages (TcI-VI), we found that strain PAH179 (TcV) was markedly less sus-
ceptible to posaconazole in vitro. Determination of parasite doubling and cycling times as
well as EdU labelling experiments all indicate that this lack of sensitivity is due to the slow
doubling and cycling time of strain PAH179. This is in accordance with ergosterol biosynthe-
sis inhibition by posaconazole leading to critically low ergosterol levels only after multiple
rounds of division, and is further supported by the lack of effect of posaconazole on the non-
replicative trypomastigote form. A washout experiment with prolonged posaconazole treat-
ment showed that, even for more rapidly replicating strains, this compound cannot clear all
parasites, indicative of a heterogeneous parasite population in vitro and potentially the pres-
ence of quiescent parasites. Benznidazole in contrast was able to kill all parasites. The work
presented here shows clear differentiation between the nitro-aromatic drugs and posacona-
zole in several assays, and suggests that in vitro there may be clinically relevant heteroge-
neity in the parasite population that can be revealed in long-term washout experiments.
Based on these findings we have adjusted our in vitro screening cascade so that only the
most promising compounds are progressed to in vivo experiments.
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Author summary
Chagas’ disease is caused by the protozoan parasite Trypanosoma cruzi, and is a major
health problem in Latin America. There is an urgent need for new treatments as the few
currently used drugs have many serious drawbacks. New potential drugs inhibiting para-
site ergosterol biosynthesis have recently failed in the clinic in spite of showing promising
results in lab-based cellular models of the disease. To understand why these may have
failed we have devised new cellular assays that predict poor performance of ergosterol bio-
synthesis inhibitors. The new assays comprise of a T. cruzi strain panel drug efficacy assay
that encompasses the six key genetic lineages and a compound washout assay that assesses
the ability of candidate drugs to kill all parasites. The ergosterol biosynthesis inhibitor
posaconazole performed poorly against the slow replicating/ cycling PAH179 strain and
in the washout assay. We conclude that a minimum number of replications are likely to
be required for posaconazole to cause a cytocidal effect and not all parasites are susceptible
to inhibition of ergosterol biosynthesis. Our new assays will allow early identification of
such compounds so that only the most promising drug candidates are progressed towards
the clinic.
Introduction
Trypanosoma cruzi is a protozoan parasite (Order Kinetoplastida, Family Trypanosomatidae)
responsible for Chagas’ disease, also known as American trypanosomiasis. T. cruzi parasites
are predominantly transmitted to humans as metacyclic trypomastigote forms (non-dividing)
in the faeces of infected haematophagous triatomine bugs at the bite site. Entry is either
through the wound or transfer to neighbouring mucosa [1]. T. cruzi transmission can also
occur congenitally, via organ transplantation, blood transfusion, or orally by ingestion of para-
site contaminated food and drink [2–5]. Chagas’ disease is a zoonotic disease which is endemic
in Latin America with an estimated 7–8 million people infected across 21 countries resulting
in 12,500 deaths per year, making it one of the leading causes of cardiovascular morbidity and
premature death in this region [6, 7]. It has a severe economic impact [8] and is also becoming
a global public health problem through human migration [9–14]. Chagas’ disease has two
phases, an initial acute phase (typically lasting 2 months) [15], followed by a chronic phase
which is life-long. Once the acute phase subsides, patients enter the chronic indeterminate
phase. Several years later approximately 30% of people display severe clinical pathologies
developing cardiac problems and 10% of cases will develop digestive disorders such as megaco-
lon and megaoesophagous, or neurological dysfunction or a combination of these [16, 17].
In addition, reactivation can occur in patients with the indeterminate chronic form if they
become immuno-compromised [18, 19].
T. cruzi is a highly genetically diverse parasite having diversified from its most recent com-
mon ancestor an estimated 3–4 million years ago [20]. T. cruzi strains have been categorised
into six major genetic lineages or discrete typing units (DTU) TcI-VI [21–24]. DTU distribu-
tion is associated with geography, ecology and transmission cycle, and it is thought that genetic
diversity between strains may be associated with variation in Chagas’ disease pathology and
outcome [23, 25]. TcI, II and V cause most human infections. TcI is widely distributed with
many silvatic reservoirs and is genetically highly diverse. DTU TcV and VI are hybrid lineages
which have originated from recent (within 60,000 years) hybridisation between TcII and TcIII
[20]. TcV and VI are almost exclusively found in domestic transmission cycles, particularly in
areas where cases of severe Chagas’ disease manifesting with megasyndromes are common
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[25–27]. TcV is also involved in 80–100% of congenital transmission cases in Argentina,
Bolivia, Southern Brazil, Chile and Paraguay [28–32]. On average congenital transmission
occurs in 5% of chronically infected mothers [33]. The success of vector control programmes
means that congenital transmission is increasingly important, indeed a recent report estimated
that 22% of new cases annually were caused by congenital transmission rather than vectorial
transmission [34]. Despite this genetic diversity and its epidemiological and likely clinical rele-
vance, a very limited number of strains are used in drug development.
The current drugs available to treat Chagas’ disease are benznidazole (2-nitroimidazole)
and nifurtimox (5-nitrofuran) which were developed over four decades ago. These nitroheter-
ocyclic compounds are most effective in the acute phase of disease [35, 36]. However, efficacy
varies geographically and there is no consistently effective treatment for established chronic
Chagas’ disease [35, 37–40], which is the most prevalent clinical presentation. These drugs can
also cause severe side effects and require long treatment duration (60–90 days) which adversely
affects patient compliance. The urgent need for new, less toxic drugs led to the identification
of ergosterol biosynthesis inhibitors as new potential chemotherapeutics. Triazole derivative
posaconazole is a selective inhibitor of the T. cruzi ergosterol biosynthesis pathway at the C14α
sterol demethylase (CYP51) level. T. cruzi requires endogenous sterols for survival and prolif-
eration at all life cycle stages [41]. Posaconazole was shown to be active against T. cruzi in vitro
and in vivo, and produced beneficial effects in combination with benznidazole in vivo [42–44].
However, these drugs failed in Phase II clinical trials with up to 92% of cases relapsing during
the 10–12 month follow-up period (as determined by detection of T. cruzi DNA in blood by
PCR) [45, 46]. A more recent Phase II trial involving asymptomatic carriers also reported high
relapse rate for posaconazole (87%), with benznidazole monotherapy giving 13% relapse dur-
ing the follow-up period with discontinuation of treatment in 32% patients receiving benzni-
dazole alone or in combination with posaconazole due to adverse side effects [47]. The lack of
translation of in vitro data and in vivo model data to clinical outcome is of clear concern. It
may be due to differences in T. cruzi strain response, drug mode of action being dependent on
parasite replication, or sub-optimal systemic drug exposure in patients [48]. Indeed there is
evidence that response to triazole drug treatment varies between T. cruzi strains in vivo [49,
50]. More recently, strain-specific variation in triazole activity was reported using an in vitro
intracellular assay where nitroheterocyclic compounds were largely active across TcI-VI and
fast acting, while marked variation in potency against T. cruzi strains was observed for posaco-
nazole [51]. In addition, using a sensitive in vivo bioluminescence imaging system to deter-
mine T. cruzi burden in tissues, it was reported that posaconazole has limited effect on both
acute and chronic T. cruzi infections in mice while benznidazole gave 100% sterile cure after
20 days treatment followed by immunosuppression to increase the detection of relapse [52].
To develop future chemotherapy against Chagas’ disease and improve translation to a suc-
cessful clinical outcome we must ensure robust in vitro assays are employed in conjunction
with reproducible in vivo models that clearly demonstrate sterile cure. To identify new pheno-
typic hits against T. cruzi our screening cascade consists of an intracellular image-based in
vitro assay using T. cruzi strain Silvio X10/7 subclone A1 (DTU TcI) and Vero host cells, fol-
lowed by rate of kill and cidality assays [53]. A CYP51 assay is also carried out so only cidal
compounds that do not have CYP51 mode of action are progressed to drug metabolism, phar-
macokinetic and in vivo efficacy studies. The mouse model uses highly sensitive non-invasive
bioluminescence imaging to detect transgenic CLBrener expressing the variant firefly lucifer-
ase RE9h [54] in BALB/c mice. This methodology provides accurate assessment of parasite
burden over time and in specific tissues at endpoints, which is difficult to achieve by PCR
analysis. To investigate potential T. cruzi strain response variation in new drug candidates we
have developed a T. cruzi strain panel of clinically relevant strains encompassing the six major
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DTUs (TcI-VI) using an in vitro image-based intracellular assay. Here we determine in vitro
efficacy of current nitrohetercyclic drugs nifurtimox and benznidazole, and failed triazole
posaconazole against the replicating amastigote form of TcI-VI strains. For comparison these
compounds were also tested in a non-replicative trypomastigote bioluminescence assay using
strains Silvio X10/7 clone A1 (TcI) and Tulahuen βgal (TcVI). Further assessment of the prolif-
eration status of intracellular parasites remaining after drug treatment was carried out. In addi-
tion, an intracellular T. cruzi washout assay was developed to determine if very low numbers
of viable parasites remain after treatment that could help explain failure in the animal model
and clinical trials.
Materials and methods
Trypanosoma cruzi in vitro culture
A panel of T. cruzi strains originally isolated from humans was established which included
one representative from each of the six major DTU’s (Table 1). TcI strain Silvio X10/7 sub-
clone A1 [55]; TcII strain Y [56], TcIII M6241 Clone 6 [57], TcIV ERA Clone 2 [58], TcV
PAH179 Clone 5 [59] and TcVI Tula Clone 2 [57]. TcI strain Silvio X10/7 subclone A1 was
provided by A. Fairlamb (University of Dundee); TcII strain Y, TcIII M6241 Clone 6, TcV
PAH179 Clone 5 and TcVI Tula Clone 2 were all donated by M. Miles (London School of
Hygiene and Tropical Medicine, LSHTM, UK); TcIV ERA Clone 2 was also obtained from
M. Miles LSHTM with agreement of Hernan Carrasco (Universidad Central de Venezuela);
CLBrener expressing pTRIX2-PpyRE9h red-shifted was obtained from J. Kelly (LSHTM, UK).
Henceforth, these strains will be referred to by name without the clone information. In
addition, our animal model strain CLBrener [60] expressing pTRIX2-PpyRE9h red-shifted
luciferase [54] was also included in the panel (CLBrenerLuc, TcVI). Tulahuen strain parasites
(TcVI) stably expressing β-galactosidase (Tulahuen βgal) [61] were not included in the T. cruzi
strain panel but were used in the trypomastigote assay. These were kindly provided by F. Buck-
ner (University of Washington, Seattle, USA).
All T. cruzi strains described above, with the exception of the Tulahuen βgal strain, were
maintained as epimastigotes in vitro at 28˚C in RTH/ FCS culture medium (RPMI1640 supple-
mented with 0.4% trypticase peptone, 0.017 M hepes, 25 μM haemin,10% heat inactivated FCS
(GE Healthcare) [62, 63]. Epimastigotes (106 ml-1) were inoculated into RTH/ FCS and grown
until a high proportion of metacyclic trypomastigote parasites were observed (~7–10 days).
Trypomastigote-rich cultures were incubated with a monolayer of Vero cells (African green
monkey kidney cells, ECCAC 84113001) at a multiplicity of infection (MOI) of 10–15 over-
night at 37˚C 5% CO2 in Dulbecco’s modified Eagles’s medium (DMEM 4.5 gL
-1 Glucose &
L-Glutamine) (Lonza) supplemented with 10% FCS (GE Healthcare). Extracellular parasites
were removed the following day by aspirating cell culture media, washing the Vero cell
Table 1. T. cruzi strain panel encompassing the six major T. cruzi discrete typing units (DTU’s) TcI-VI.
DTU T. cruzi Strain ID Host Date Origin
Tc I Silvio X10/7 Clone A1 Human 1979 Para´, Brazil
Tc II Y Human 1953 São Paulo, Brazil
Tc III M6241 Clone 6 Human 1988 Para´, Brazil
Tc IV ERA Clone 2 Human 1999 Anzoa´tegui, Venezuela
Tc V PAH179 Clone 5 Human 2000 Chaco, Argentina
Tc VI Tula Clone 2 Human 1988 Tulahue´n, Chile
Tc VI CLBrener Triatoma Infestans 1963 Rio Grande do Sul, Brazil
https://doi.org/10.1371/journal.pntd.0006612.t001
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monolayer with serum-free DMEM three times, followed by addition of fresh complete
DMEM. T. cruzi infected Vero flasks were maintained at 37˚C 5% CO2, DMEM/ FCS replaced
every 48h until trypomastigotes emerged from Vero cells to be used to set-up new Vero cell
infections. The routine cycling time through Vero cells varied considerably between strains
from 3 to 12 days, therefore, for more slowly cycling strains (PAH179 & Tula), infected Vero
cells were pre-incubated for 3 days prior to assay plating to coordinate parasite cycling times
through Vero cells.
Tulahuen βgal parasites were maintained in culture by weekly infection of LLC-MK2
cells (Rhesus macaque kidney epithelial cells) in DMEM (Life-Technologies) supplemented
with 2% FBS (Biowest, USA) and 100 Uml-1 penicillin and 100 μgml-1 streptomycin (Sigma-
Aldrich). Trypomastigote forms were obtained from the supernatants of LLC-MK2 infected
cultures harvested between days 5 and 9 of infection.
Host cell culture
Vero cells were maintained at 37˚C 5% CO2 in DMEM (Lonza) supplemented with 10% FCS
as described above. Vero cells were sub-cultured every 2 days at a ratio of 1:5 after 5 min treat-
ment with Trypsin-EDTA (Gibco).
LLC-MK2 cells were cultivated in DMEM (Life-Technologies) supplemented with 10% FCS
(Biowest, USA), 100 Uml-1 penicillin and 100 μgml-1 streptomycin (Sigma-Aldrich) at 37˚C,
5% CO2 and>95% humidity. This cell line was maintained twice a week at a ratio of 1:10.
Leishmania donovani in vitro culture
Leishmania donovani strain MHOM/ET/67/HU3:LV9 originally isolated from a patient in
Ethiopia 1967 were maintained as promastigotes at 28˚C in RPMI1640 (Sigma, Dutch modifi-
cation) supplemented with 20% FCS (Hyclone), 100 μM adenine, 20 mM MES hydrate, 5 μM
haemin, 6-biopterin 3 μM, biotin 1 μM, 1% penicillin and streptomycin. Parasites were estab-
lished at 105 ml-1 and sub-cultured every 3 days.
T. cruzi strain genotyping
Total genomic DNA was isolated from T. cruzi epimastigote or trypomastigote cultures using
Qiagen DNAeasy tissue & blood kit according to manufacturer’s instructions.
Single-locus typing assay. T. cruzi TcSC5D gene encodes a putative C-5 sterol desaturase
(TcCLB.473111.10, TcCLB.507853.10), this was amplified by PCR followed by direct sequenc-
ing to determine DTU-specific genotypes using eight key discriminating single nucleotide
polymorphisms (SNP’s) as previously described [64]. Briefly, a 832bp TcSC5D fragment was
amplified under the following PCR conditions: 50 pmol TcSC5D-forward (5´-GGACGTGG
CGTTTGATTTAT-3´) & reverse primers (5´-TCCCATCTTCTTCGTTGACT-3´), 100 ng
genomic DNA, Platinum PCR Supermix High Fidelity (ThermoFisher Scientific) in a final vol-
ume of 50 μl. Samples were denatured at 94˚C for 5 min, followed by 35 cycles at 94˚C 30 s,
58˚C 30 s, 72˚C 30 s, and extension at 72˚C for 5 min. Amplification products were visualised
on 1.2% agarose with ethidium bromide as a single 832 bp product, and subsequently
sequenced with the same PCR primers using Applied Biosystems 3730 DNA Analyser. Chro-
matograms were analysed using Chromas software and alignments generated using Clustal
Omega to identify nucleotides at key position 138, 168, 336, 495, 618, 648, 657 and 747 and
determine DTU assignment TcI-VI (S1 Table).
Triple assay. DTU assignment was made based on genotypes for three PCR-based assays:
the amplicon size polymorphism of the 24S rRNA locus [65] and two restriction fragment
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length polymorphism assays based on SNPs in the HSP60 & GPI loci [66]. The combined geno-
types were used to infer the DTU according to the scheme described by Lewis et al [67].
Amplification reactions contained 0.2 mM of each dNTP, 1.5 mM MgCl2, 1 pmol μl-1 of
each primer, 1 Unit of Taq DNA polymerase (Promega, UK) and approximately 10 ng gDNA.
For the 24S rDNA, PCR primers D71 (5’-AAGGTGCGTCGACAGTGTGG-3’) and D72
(5’-TTTTCAGAATGGCCGAACAGT-3’) were used and conditions comprised an initial
denaturation step of 94˚C for 3 min then 27 amplification cycles (94˚C for 1 min, 60˚C for 1
min, 72˚C for 1 min) followed by a final elongation step at 72˚C for 5 min. Amplicon sizes
were visualised on 1X Tris-acetate-EDTA (TAE), 3.5% NuSieve 3:1 agarose (Lonza) gels.
For GPI and HSP60, PCR amplification conditions comprised an initial denaturation step
of 3 min at 94˚C followed by 4 cycles (94˚C for 30 s, 64˚C for 30 s, 72˚C for 1 min) followed by
28 cycles (94˚C for 30 s, 60˚C for 30 s, 72˚C for 1 min) and then a final elongation step at 72˚C
for 10 min. GPI primers were 5’-GGCATGTGAAGCTTTGAGGCCTTTTTCAG-3’ (Fwd)
and 5’-TGTAAGGGCCCAGTGAGAGCGTTCGTTGAATAGC-3’ (Rev). HSP60 primers
were 5’-GTGGTATGGGTGACATGTAC-3’ (Fwd) and 5’-CGAGCAGCAGAGCGAAACAT-
3’ (Rev). For restriction enzyme digestion, 10 μl of PCR product (typically ~1 μg) was digested
with 0.25 U μl-1 of either HhaI for GPI or EcoRV for HSP60 for 4 h at 37˚C. Restriction frag-
ment sizes were visualised on 1X TAE, 2% agarose gels.
Compound handling
Compounds included current treatments for Chagas’ disease benznidazole and nifurtimox
(both from Sigma), and CYP51 inhibitor posaconazole (Sequoia Research Products). Com-
pound (250 nl in DMSO) was dispensed using LabCyte ECHO into each well (Corning black
flat bottomed 384-well plates for the intracellular amastigote assay; Greiner white 384-plates
for the trypomastigote assay). Ten-point potency curves were generated (one in three dilu-
tion), with technical duplicates for the intracellular assay and in triplicate for the trypomasti-
gote assay. All potency determinations were performed a minimum of 3 independent times. A
top concentration of 50 μM was used for benznidazole and nifurtimox, and 1 μM for posaco-
nazole in the intracellular assay (all wells contained 0.5% DMSO), while a top concentration of
50 μM was used for all three drugs in the trypomastigote assay. Drug potencies are reported as
pEC50 which is–Log (EC50 [M]).
T. cruzi intracellular assay
Silvio X10/7, Y, M6241, ERA and CLBrenerLuc trypomastigotes were incubated at 37˚C 5%
CO2 with 1.6×107 Vero cells overnight at MOI10 in a T225 flask. Extracellular parasites were
removed by aspirating cell culture supernatant, and washing Vero monolayer with 10 ml
serum-free DMEM three times. Vero cells were then harvested by trypsinization and dis-
pensed at 2×103 per well (50 μl in DMEM/ 1% FCS) into 384 well plates pre-stamped with
drug in DMSO using automated washer/ dispenser EL406 and liquid handling software (Bio-
tek). Plates were then incubated at 37˚C in 5% CO2 for 72, 96 and 120 h.
Plates were subsequently fixed with 4% formaldehyde for 20 min, permeabilised and
stained with 5 μgml-1 Hoechst 33342/ 0.1% Triton/ PBS Thimerosal 20 min. Automated imag-
ing was performed by the Operetta high content imaging system using 20x objective (Perki-
nElmer). Images were analysed with an algorithm generated in Columbus (PerkinElmer) to
segment Vero cell nuclei, Vero cell cytoplasm and parasite nuclei/ kinetoplasts, reporting
number of amastigotes per Vero cell and total number of Vero cells. Compound potencies
against T. cruzi parasites were calculated in IDBS Activitybase using total number of amasti-
gotes per well and Vero toxicity curves generated using number of host cells. All data was
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normalised to percent inhibition based on the raw data values for the 100% effect control
(50 μM nifurtimox) and the 0% effect control (DMSO) on each plate at each time point. Curve
fitting was carried out using a four-parameter equation as previously described [68].
Parasite replication
To determine amastigote replication rates for each strain, the T. cruzi intracellular assay was
established as described above with identical plates set-up for each strain and fixed daily to
determine number of amastigotes from Day 0 (day of plating) up to Day 5. T. cruzi amastigote
doubling time (DT) was determined by fitting the 0–72 h growth data to exponential expres-
sion N = N0.e
Ke.t (N = number of cells at time t, N0 = number of cells at t = 0 h, Ke is the expo-
nential constant). DT was calculated as ln(2)/Ke. There are 32 technical replicates for each
time point per plate, and at least 3 biological replicates for each strain.
T. cruzi trypomastigote assays
Silvio X10/7 trypomastigotes were harvested from infected Vero cells in a T225 flask infection
set-up at MOI 5 for 5 days. Trypomastigotes (5×104 per well) in 50 μl of DMEM/ 10% FCS
were dispensed into white 384 plates (Greiner) pre-stamped with 250 nl compound. Plates
were incubated at 37˚C in 5% CO2 for 24, 48 and 72 h. Cell Titer-Glo cell viability solution
(Promega) was added to each well (50 μl) incubated at room temperature for 10 min and lumi-
nescence read by Envision plate reader (Perkin Elmer). This assay quantifies the amount of
ATP present which is directly proportional to the number of metabolically active cells. All data
was normalised as described above (100% effect control 50 μM nifurtimox, 0% effect control
DMSO).
Tulahuen βgal trypomastigotes were harvested from LLC-MK2 host cells after 5–9 days
infection. Trypomastigotes (5×104 per well) in 50 μl of DMEM/ 2% FCS/ 100 Uml-1 penicillin
and 100 μgml-1 streptomycin were dispensed and processed as described above.
Cell proliferation, antibody labelling and imaging
Proliferation of Silvio X10/7 trypomastigotes was measured using Click-iT Plus EdU Alexa-
Fluor 488 Imaging Kit (ThermoFisher Sci). EdU (5-ethynyl-2-deoxyuridine) is a nucleoside
analog of thymidine that is incorporated into newly synthesised DNA. Detection is via a cop-
per catalysed covalent click reaction between picolyl azide which is contained in the EdU and
an alkyne contained in the AlexaFluor 488 label. Silvio X10/7 trypomastigotes (2×107) were
harvested from Vero cells, washed with PBS, labelled live with 10 μM EdU labelling solution
for 2 h at 37˚C 5% CO2. L. donovani LV9 mid-log promastigotes were included as a replicating
cell control and incubated at 28˚C 2 h. After media aspiration, cells were fixed in 4% formalde-
hyde/PBS for 20 min, washed three times with 3% fatty acid free BSA blocking solution (BB
International), permeabilised with 0.5% Triton X-100 20 min, washed with blocking solution,
and incubated with 100 μl of Click-iT Plus reaction cocktail for 30 min in the dark. Cells were
washed twice and incubated in blocking reagent overnight at 4˚C. Edu labelled cells were also
labelled with L. major rabbit polyclonal anti-PFR1 (paraflagellar rod) antibody [69] 1:200 in
blocking solution for 1 h. Parasites were washed in block, incubated with goat anti-rabbit IgG
AlexaFluor-647 for secondary detection of anti-PFR 1 h (1:200; ThermoFisher Sci), washed in
PBS and resuspended in 5 μgml-1 Hoechst 33342 (DNA stain) 20 min. Parasites were subse-
quently washed in PBS, resuspended in 100 μl PBS and allowed to adhere to poly-D-lysine
coated 96 well Cell Carrier black plates (Perkin Elmer) for 20 min before imaging with the
Operetta high content microscope 40XHi NA objective. EdU (Ex/ Em 495/ 519 nm), PFR/
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AlexaFluor 647 (Ex/ Em 650/ 670 nm), Hoechst (Ex/ Em 350/ 461 nm) plus bright field, ten
1 μm slice stack.
Silvio X10/7 and PAH179 infected Vero cells (MOI10) were also labelled with EdU and
Hoechst as described above. However, labelling was performed on infected Vero cells which
were already adherent on 96 well black Cellbind plates (Corning) seeded at 4×103 and 103 per
well after 5 days treatment with 1 μM posaconazole, 50 μM benznidazole, 5 μM nifurtimox or
0.5% DMSO. Control wells without EdU labelling were also set-up for each condition and
were processed the same way but without incubation with EdU labelling solution. Plates
were imaged using the Operetta high content microscope with 40X objective for EdU, Hoechst
and bright field as above, five 1 μm slice stack, 16 fields/well. An algorithm was generated in
Columbus to determine percent infected cells, percent EdU positive Vero and EdU positive
intracellular parasites. For publication purposes deconvolution images were acquired.
T. cruziwashout assay
Vero cells (1.6 ×107) were infected at MOI 5 with Silvio X10/7 trypomastigotes in MEM media
(Gibco) containing 10% FCS (Hyclone) followed by washing of the monolayer to remove any
extracellular trypomastigotes. Total Vero infection time with Silvio X10/7 trypomastigotes
prior to compound treatment was either 40 h or 16 h. Infected cells were trypsinised and plated
in T25 flasks (1.8×106 cells per flask, MEM, 1% FCS) or incubated for a further 24 h prior to
trypsinisation and plating. Infected cells were incubated with compounds at the indicated con-
centrations for either 8 days or 16 days. Every 4 days the media was replaced with fresh com-
pound-containing media. After the treatment period, monolayers were washed extensively.
The cultures were then maintained, replacing media twice weekly, until trypomastigotes could
be observed by light microscopy. Observations were carried out twice weekly for up to 60 days
post washout.
Results
T. cruzi strain genotyping
All T. cruzi strains included in this study were confirmed to be the expected DTU by either
the triple assay (PCR product size polymorphism of the 24S rRNA locus; PCR-RFLP based on
SNP’s in the GPI and HSP60 loci) and/ or the single assay (DTU discriminating SNP’s in T.
cruzi TcSC5D gene) (S2 Table, S1 Fig).
T. cruzi amastigote growth rate & level of Vero cell infection varies between
strains
Growth of intracellular amastigotes varies between T. cruzi strains. Silvio X10/7, M6241, Tula
and CLBrenerLuc strains demonstrated the fastest doubling times and higher starting (day 0)
percent infected Vero cells. Silvio X10/7 and M6241 gave similar Vero cycling times (4–5 days
between infection and egress of parasites) while CLBrenerLuc and Tula cycled every 6–8 d
(Table 2). Y, ERA and PAH179 strains displayed the slowest doubling times (24 to 26 h).
However, Vero cycling times varied considerably with Y and ERA cycling rapidly (every 3–4
days), while PAH179 had the slowest cycling time (8–12 days). The duration of our established
primary T. cruzi screening assay using Silvio X10/7 infected Vero cells is 72 h. To improve
assessment of compounds that may have modes of action that are replication dependent, the
T. cruzi strain panel assay was extended to 120 h post-infection (Table 2). At this time point Y
strain trypomastigotes had emerged and some re-infection was observed. Although there was
some variation in doubling time between biological replicates, strain PAH179 achieved the
Development of Trypanosoma cruzi in vitro assays for Chagas’ disease drug discovery
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006612 July 12, 2018 8 / 22
lowest number of divisions at 120 h and reached stationary growth phase at lower total amasti-
gote counts than other strains (Table 2, S2 Fig). Strains Y and PAH179 gave the lowest starting
percent infected Vero (day 0). Despite differences between strains in infection level and dou-
bling times the total number of amastigotes counted at the assay end point (120 h) was always
more than 103 per well for all T. cruzi panel strains providing a sufficient window between the
0% (DMSO) and 100% (50 μM nifurtimox) effect controls to generate potency curves.
Intracellular assay—Posaconazole shows poor activity against slowly
replicating/ cycling T. cruzi
Nifurtimox was active across all seven T. cruzi strains from six major DTUs with a maximum
six-fold difference in potency observed between strains (CLBrenerLuc v Y) at 120 h (Table 3;
Fig 1A illustrates nifurtimox dose response data for three key DTU strains). Benznidazole
showed good activity across five T. cruzi strains with a maximum inhibition of at least 99% rel-
ative to nifurtimox at 120 h (Table 3). However, reduced efficacy against strain Y was observed.
Benznidazole was 5–13 fold less potent against strain Y than other strains at 120 h reaching
90% maximum inhibition (Table 3, Fig 1B).
The triazole posaconazole, was active against five T. cruzi strains at low nanomolar concen-
trations at 120 h (Table 3, Fig 1C). However, posaconazole was more slowly acting than the
nitroheterocyclic compounds tested, with clear differences between the strains. While >90%
inhibition was observed for Silvio X10/7, Y, and M6241 at 72 h, ERA, Tula and CLBrenerLuc
showed<75% inhibition (S3 Table). By 120 h>90% inhibition was observed against these
strains (Table 3, Fig 1C). Interestingly, posaconazole showed only minimal activity against
strain PAH179. Intracellular T. cruzi inhibition was only 17% at 72 h, reaching a maximum of
Table 2. T. cruzi strain panel amastigote doubling time (DT), average ±SD, calculated using 0-72h growth curve data [see Methods] for at least 3 biological repli-
cates. This value was used to calculate the number of divisions in 72 h. Number of divisions in 120 h were calculated from DT determined using number of amastigotes at
0 and 120 h. Cycling time defines the time in days between the start of Vero cell infection with T. cruzi tissue culture derived trypomastigotes and the emergence of trypo-
mastigote parasites. Level of parasite infection (Day 0) for each strain represented as percent infected Vero cells (average± SD).
Doubling Time (h) Divisions/ 72 h Divisions / 120 h Cycling times (d) % infected Vero
Silvio X10/7 19.6 ± 1.5 3.7 ± 0.3 4.6 ± 1.3 4–5 31 ± 15
Y 25.3 ± 5.8 3.0 ± 0.7 3.5 ± 1.7 3 11 ± 10
M6241 18.9 ± 1.6 3.8 ± 0.3 4.3 ± 0.7 4–5 25 ± 15
ERA 24.3 ± 4.8 3.0 ± 0.6 3.9 ± 0.8 4 30 ± 16
PAH179 25.6 ± 7.4 3.0 ± 0.8 3.3 ± 1.2 8–12 16 ± 11
Tula 19.5 ± 2.9 3.7 ± 0.5 5.7 ± 1.8 7–8 23 ± 19
CLBrenerLuc 19.5 ± 2.8 3.7 ± 0.6 3.9 ± 1.3 6–7 32 ± 21
https://doi.org/10.1371/journal.pntd.0006612.t002
Table 3. Drug efficacy against T. cruzipanel strains at 120 h. pEC50 = –Log (EC50 [M]), average of at least three biological replicates ± SD. Additional data for 72 h and
96 h time points available in S3 and S4 Tables respectively.
T. cruzi Strain ID Nifurtimox Benznidazole Posaconazole
pEC50 Max inhibition (%) pEC50 Max inhibition (%) pEC50 Max inhibition (%)
Silvio X10/7 6.1 ± 0.2 100 ± 1 5.7 ± 0.2 100 ± 2 8.6 ± 0.1 97 ± 3
Y 5.7 ± 0.2 103 ± 5 4.8 ± 0.1 90 ± 4 8.6 ± 0.2 108 ± 10
M6241 6.0 ± 0.1 105 ± 5 5.5 ± 0.2 105 ± 5 8.7 ± 0.3 104 ± 6
ERA 6.3 ± 0.0 103 ± 3 5.9 ± 0.1 103 ± 3 8.9 ± 0.1 91 ± 9
PAH179 6.3 ± 0.2 102 ± 5 5.7 ± 0.1 102 ± 5 <6.0 65 ± 14
Tula 6.3 ± 0.4 100 ± 1 5.9 ± 0.1 99 ± 2 8.4 ± 0.1 94 ± 5
CLBrener Luc 6.5 ± 0.1 100 ± 2 5.9 ± 0.2 101 ± 2 8.5 ± 0.2 94 ± 6
https://doi.org/10.1371/journal.pntd.0006612.t003
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65% at 120 h (Tables S3 & 3, Fig 1C). After 72 h and 96 h treatment there was little discernible
effect of posaconazole on intracellular PAH179 parasite counts while at 120 h parasite numbers
started to decrease at high compound concentrations but not to the extent observed for other
strains (Fig 2). (S3 Fig illustrates non-normalised dose-response data for nifurtimox, benznida-
zole and posaconazole at 120h for all strains). This poor activity against the strain that repli-
cates and cycles most slowly suggests posaconazole mode of action is replication dependent,
possibly requiring completion of several replication cycles for full activity.
Trypomastigote assay—Posaconazole has minimal activity against
trypomastigote stage parasites
Nifurtimox and benznidazole were both active against Silvio X10/7 (TcI) and Tulahuen βgal
(TcVI) trypomastigote parasites (non-replicating stage) (Table 4, Fig 3A, 3B, 3D and 3E).
However, posaconazole was not active against Tulahuen βgal trypomastigotes and poorly
active against Silvio X10/7 at 72 h (Table 4, Fig 3C and 3F), with a very large drop-off in
potency (> 3000-fold at 72 h) between the intracellular and trypomastigote assays, again sug-
gesting posaconazole efficacy is replication dependent.
EdU labelling- Non-replicating trypomastigotes and replicating amastigote
stage PAH179 strain parasites remain after posaconazole treatment
The above data are in agreement with posaconazole being inactive against parasites that do not
go through a sufficient number of cell divisions. To determine if PAH179 parasites remaining
after posaconazole treatment are non-replicating forms we assessed the effect of posaconazole
on the fraction of replicating parasites using EdU (nucleoside analog of thymidine) labelling to
identify cells in S-phase of growth. As a positive proliferative cell control, EdU labelling of L.
donovani LV9 mid-log promastigotes was performed where EdU staining was observed in 54%
of LV9 (118 cells analysed) co-localising with the parasite nucleus (S4A Fig). This is a non-syn-
chronous population but it also cannot be ruled out that not all replicating cells are detected
Fig 1. Drug efficacy against T. cruzi intracellular amastigotes. Strains Silvio X10/7, Y and PAH1790 assessed after 5 days treatment
with nifurtimox (A) benznidazole (B) and posaconazole (C). (Representative dose-response curves of at least 3 biological replicates
normalised to 0% effect DMSO and 100% effect 50 μM nifurtimox controls. Average±SD). The x axis is the Log of the compound
concentration in Molar.
https://doi.org/10.1371/journal.pntd.0006612.g001
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under these labelling conditions. As expected, no EdU labelling was detected in Silvio X10/7
trypomastigotes (161 cells analysed) which are a non-replicating developmental form (S4C
Fig). Presence of a flagellum was detected by PFR1 labelling in both LV9 and Silvio X10/7 con-
firming Silvio X10/7 trypomastigote morphology in conjunction with Hoechst staining reveal-
ing characteristic positioning of nuclei and kinetoplasts (S4C Fig).
EdU labelling of intracellular Silvio X10/7 and PAH179 was subsequently performed. After
5 days incubation without drugs (0.5% DMSO, vehicle control) 46% of Silvio X10/7 and 13%
of PAH179 amastigotes were EdU positive (Fig 4B). After 5 days treatment with 5 μM nifurti-
mox, 50 μM benznidazole, or 1 μM posaconazole, a significant reduction in total number of
Silvio X10/7 amastigotes and EdU positive amastigotes was observed (Fig 4A and 4B Anova
p<0.001). These drug concentrations were chosen as they show good activity against Silvio
X10/7 but are not toxic to Vero cells. Of the Silvio X10/7 amastigotes remaining after each
treatment only 4–5% of remaining parasites were categorised as EdU labelled. However,
visual inspection of the images showed that the majority of remaining parasites were EdU false
Fig 2. Raw dose-response data for T. cruzi intracellular amastigotes after treatment with posaconazole at 72 h, 96 h and 120 h
for strains Silvio X10/7 (A-C) and PAH179 (D-F) (3 biological replicates shown). The x axis is the Log of the compound
concentration in Molar.
https://doi.org/10.1371/journal.pntd.0006612.g002
Table 4. Efficacy of nifurtimox, benznidazole and posaconazole against T. cruzi Silvio X10/7 and Tulahuen βgal trypomastigotes at 72 h. pEC50 = –Log (EC50 [M]),
average of at least three biological replicates ± SD. Additional data for 24 h and 48 h time points available in S5 Table.
T. cruzi Strain ID Nifurtimox Benznidazole Posaconazole
pEC50 Max inhibition (%) pEC50 Max inhibition (%) pEC50 Max inhibition (%)
Silvio X10/7 5.8 ± 0.1 100 ± 0 5.4 ± 0.0 100 ± 0 4.7 ± 0.2 70 ± 4
Tulahuen βgal 6.1 ± 0.0 100 ± 1 5.2 ± 0.0 100 ± 1 <4.3 -5 ± 2
https://doi.org/10.1371/journal.pntd.0006612.t004
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positive detections by the image analysis algorithm (Fig 4C bottom three panels). After 5 days
5 μM nifurtimox, or 50 μM benznidazole treatment, a significant reduction in total intracellu-
lar PAH179 parasites was also observed (Anova P<0.005) with only 2–6% EdU positive (Fig
4A and 4B). Again, upon image visualisation, no EdU positive remaining parasites were
observed (Fig 4D middle two panels). However, 5 days 1 μM posaconazole treatment only
cleared half of the intracellular parasites, and 12% of the remaining parasites were EdU positive
(Fig 4A and 4B) which is a similar proportion as DMSO treatment (13%). Thus, posaconazole
is not active against non-replicating intracellular PAH179 strain parasites and replicating
PAH179 can be refractory to killing by posaconazole, consistent with parasite death only after
several replication cycles (Fig 4D bottom panel). Although it is possible that slowly replicating
parasites would not be detected under these EdU labelling conditions, this method does detect
replicating T. cruzi. Individual images for each strain are shown in S5 and S6 Figs. Infected
Vero control wells not incubated with EdU show no background staining (S7 and S8 Figs).
The proportion of EdU labelled Vero cells did not significantly change with any of the drug
treatments (Anova p>0.05) (S9 Fig).
T. cruziwashout assay—Benznidazole is curative in vitro and posaconazole
is not
The experiments above do not demonstrate that the nitroheterocyclic compounds can kill
all parasites, neither do they exclude that longer treatment with posaconazole could be effica-
cious. To address these questions a washout experiment was performed using Silvio X10/7
infected Vero cells treated for either 8 or 16 days with high concentrations of benznidazole or
Fig 3. Drug efficacy against T. cruzi trypomastigotes. Silvio X10/7 (A-C) and Tulahuen βgal (D-F) trypomastigotes after 24, 48 and
72 h treatment with nifurtimox (A & D), benznidazole (B & E) and posaconazole (C & F). (Dose-response curves of three biological
replicates. Average±SD). The x axis is the Log of the concentration of the drug in Molar.
https://doi.org/10.1371/journal.pntd.0006612.g003
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posaconazole (12.5–50 times EC50). Treated cells were then maintained for up to 60 days and
culture flasks were assessed for presence of trypomastigotes. Lack of recrudescence within
60 days was considered evidence for complete inactivation of all parasites. Recrudescence of
parasites was seen for both compounds with the 8 day treatment regimen, but emergence of
trypomastigotes was significantly delayed with benznidazole compared to posaconazole (benz-
nidazole relapse: 14 to 21 days after washout, posaconazole: 3 days after washout) (Table 5).
After 16 days of treatment no parasite recrudescence was seen with benznidazole for over 60
days, suggesting it is able to kill all parasites in vitro. Posaconazole treated cells did relapse,
with parasites emerging after only 11 days.
Fig 4. Detection of cells in S phase growth by EdU labelling of intracellular T. cruzi strains Silvio X10/7 and PAH179. Number of amastigotes per well
(average ±SD) determined by Hoechst staining after 5 days treatment with DMSO, 5 μM nifurtimox, 50 μM benznidazole and 1 μM posaconazole (A). Percent
EdU positive amastigotes (B) after treatments described above using the automated image analysis algorithm. Imaging by HTS microscopy of Silvio X10/7 (C)
and PAH179 (D) infected Vero labelled with EdU AlexaFluor 488 and Hoechst, treated for 5 days with DMSO, 5 μM nifurtimox, 50 μM benznidazole and
1 μM posaconazole. Parasites remaining after treatment are highlighted by white arrows (Hoechst), replicating parasites remaining after treatment are
highlighted by red arrows (EdU AlexaFluor488). Bar 10μm.
https://doi.org/10.1371/journal.pntd.0006612.g004
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Discussion
Here we describe development of a T. cruzi strain panel intracellular assay and a washout assay
to test the ability of compounds to show activity across the six main T. cruzi DTU’s and achieve
sterile cure in vitro. The purpose of this work is to assess if these assays could improve transla-
tion from in vitro cellular assays to in vivo efficacy.
In the strain panel we observed variation in both doubling time and host cell cycling time
between strains, with PAH179 (TcV) displaying both the slowest replication rate and longest
cycling time. The reported amastigote doubling times are estimates using day 0 to day 3
counts. The actual replication rates may be higher than we report for fast cycling parasites
such as the Y strain which cycles every 3 days as extracelluar trypomastigotes are removed by
washing before staining and counting. In addition, growth rate and cycling time of some
strains increased over time in culture. However, the PAH179 strain continued to be the slowest
cycling strain with a minimum of 8 days before trypomastigotes emerged.
Interestingly we observed strain-dependent differences for the drugs tested. In general the
nitroheterocyclic compounds nifurtimox and benznidazole were active across strains, with a
lower level of potency against the Y strain (TcII), especially for benznidazole, whereas posaco-
nazole was markedly less active against PAH179 (TcV), suggesting that replication and cycling
times may affect posaconazole efficacy. This is supported by the very poor activity of posacona-
zole against non-replicative trypomastigotes. Our results align with the data generated by
Moraes et al., in their U2OS intracellular assay strain Y cycled every 4 days and was the least
sensitive to benznidazole and nifurtimox (together with strain Dm28c TcI) [51] [strain Y has
previously been characterised as partially resistant [70]]. Furthermore, in Moraes et al. ERA
clone 2 (TcIV) was partially resistant to CYP51 inhibition, not reaching 100% inhibition
which we also observed, while 92–80 clone 2 (TcV) showed the highest level of resistance giv-
ing a maximum inhibition of only 27% against posaconazole [51]. Interestingly, not only is
strain 92–80 clone 2 the same DTU as strain PAH179 but Moraes et al. state it grows very
slowly. A difference between the studies is that we did not see the low maximum inhibition
with CLBrenerLuc for posaconazole that was observed by Moraes et al. using wild type
CLBrener.
A previous report indicates that endogenous sterols need to be depleted before cell death
occurs [42]. Our finding that posaconazole has very little effect on non-replicative trypomasti-
gotes or that it is less active against more slowly replicating / cycling T. cruzi strains supports
this conclusion. This suggests that several replications are required to see an effect in the pres-
ence of CYP51 inhibition. This is further supported by the EdU labelling experiment which
shows that the fraction of actively replicating amastigotes in strain PAH179 is not changed by
posaconazole treatment. Thus, replication per se does not provide sensitivity to CYP51 inhibi-
tion, instead a number of rounds of replication are required to see a cytocidal effect. However,
it is possible that slow replication/ cycling correlates to another genetic factor which is directly
involved in drug sensitivity / resistance.
Table 5. T. cruziwashout experiment with benznidazole and posaconazole treated Silvio X10/7 infected Vero cells. Regimen indicates the number of continuous days
the cells were treated with each concentration. Compounds were replaced every 4 days. Relapse day was the first day trypomastigotes can be observed by light microscopy
in culture after washout, negative numbers indicate that trypomastigotes were observed prior to washout.
Compound DMSO Benznidazole Posaconazole
Regimen 8 d 16 d 8 d 16 d 8 d 16 d
Concentration (fold EC50) 0 12.5 25 50 25 50 12.5 25 50 50
Relapse Day -4 -12 14 17 21 >60 >60 3 3 3 11 11
https://doi.org/10.1371/journal.pntd.0006612.t005
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A key result presented here is that long-term in vitro washout experiments, with the fast-
replicating strain Silvio X10/7, show very clear differentiation between the nitroheterocyclic
drugs and posaconazole. In particular, we demonstrate that even 16 days treatment with
posaconazole at 50 fold the EC50 cannot prevent parasite recrudescence, whereas benznida-
zole treatment is able to prevent parasite recrudescence. Cal et al. [71] have previously car-
ried out washout experiments with the same compounds but the conclusions from their
study are limited by the short treatment duration used (4 days versus 16 days here) and
short washout period (7 days versus 60 days here). The authors show that 4 days treatment
with posaconazole does not kill all amastigotes, as could be expected from its slow rate-of-
kill [53] and due to the relatively short washout period they could not unequivocally demon-
strate complete killing of all parasites with benznidazole. Another key finding we present is
that benznidazole does not prevent relapse after 8 days treatment, which is interesting as
nearly all parasites are killed within 96 h of treatment [51, 53, 71]. Dormant parasites that
are less susceptible to benznidazole in vitro have recently been reported [72] and our data
supports the existence of such a subpopulation of persister parasites. Sa´nchez-Valde´z et al.
further demonstrated that the relapsed parasites have not acquired permanent resistance to
benznidazole. Importantly, the long interval between benznidazole washout and relapse (2
weeks) demonstrates the need for long-term in vitro washout assays to assess compounds
Fig 5. Updated in vitro screening cascade for Chagas’ disease with addition of the newly developed T. cruzi strain
panel and washout assays. (Cpd, compound; TA, turnaround time).
https://doi.org/10.1371/journal.pntd.0006612.g005
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and potentially the need for an extensive assessment period after immunosuppression in the
in vivo model if sterile cure is to be demonstrated. Our findings correlate well with results
from mouse model studies where posaconazole is not curative [52] and benznidazole treat-
ment generally gives a much higher cure rate after 20 days compared to 10 days treatment
[44, 73, 74].
Taken together we present three distinct in vitro assays where benznidazole performs well
and posaconazole fails: the slow replicating / cycling strain potency assay, the trypomastigote
assay, and the extended duration washout assay. These important differences offer a likely
explanation for the poor performance of the CYP51 inhibitors E1224 and posaconazole in clin-
ical trials [45–47, 75].
We have incorporated these findings into our in vitro screening cascade for Chagas’ disease
to improve translation. Hits are now selected from our 72 h single point intracellular assay and
progressed to a cidal potency assay, these are then assessed for CYP51 mode of action. We
now move representatives of non-CYP51 inhibitor series to a 5 day T. cruzi strain panel assay
and the washout assay (>60 days). We also run compounds in our trypomastigote assay to
determine efficacy against non-replicating stage parasites but, as is it not yet clear if trypomas-
tigote killing is required for in vivo efficacy, this assay is not on the critical path of our in vitro
screening cascade (Fig 5). While the inclusion of the T. cruzi strain panel allows us to assess a
substantial level of genetic diversity by including one representative from each DTU, it is
impossible to cover all T. cruzi variability, including intra-lineage variability.
Ultimately drugs will not only have to kill all disease-causing developmental forms, but also
have the right properties to reach all the parasite reservoirs. This may be very challenging for a
single non-reactive compound and combination therapy to address these issues may be the
most likely route to success. As the current Chagas’ pipeline is very sparse there is a clear need
for new anti-trypanosomal compounds with diverse modes of action.
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with EdU AlexaFluor 488 and Hoechst. Parasites remaining after treatment are highlighted by
white arrows. Bar 20 μm.
(TIFF)
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(A) 5 μM nifurtimox (B) 50 μM benznidazole (C) and 1 μM posaconazole (D) labelled with
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